HLA-DX Inhibitors

The chemical class of HLA-DQβ2 inhibitors encompasses a range of compounds that indirectly affect the activity of the HLA class II histocompatibility antigen, DQ beta 2 chain, through various mechanisms related to antigen processing and presentation. These inhibitors primarily target different stages and components of the immune response pathway, thereby influencing HLA-DQβ2 function. Compounds like Chloroquine and Hydroxychloroquine work by altering endosomal pH, which is crucial for antigen processing, a key step in HLA-DQβ2 mediated antigen presentation. Brefeldin A and Monensin disrupt protein transport and Golgi apparatus function, respectively, affecting the proper presentation of antigens by HLA molecules.

Additionally, Colchicine, by disrupting cytoskeletal functions, and Tunicamycin, by inhibiting N-linked glycosylation, can potentially impact antigen presentation pathways relevant to HLA-DQβ2. Immunosuppressants such as Cyclosporin A, FK506 (Tacrolimus), and Rapamycin modulate different aspects of T cell function and immune cell activation, which are critical for the effective functioning of HLA-DQβ2 in antigen presentation. Furthermore, compounds like Leupeptin, MG132, and Lactacystin, which inhibit lysosomal proteases and proteasomes, respectively, can affect the generation of antigen peptides that are presented by HLA-DQβ2.